AN2 Therapeutics (ANTX) vs Atrium Therapeutics (RNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Atrium Therapeutics is the larger company by market cap ($131.2 million vs $127.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | RNA |
|---|---|---|
| Share price | $3.38 | $7.67 |
| Market cap | $127.55M | $131.20M |
| 1-day change | -6.11% | -1.92% |
| YTD return | +196.49% | — |
| 1-year return | +184.03% | — |
| EPS (TTM) | $-1.05 | $-5.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-35.17M | — |
| 52-week high | $7.19 | $16.77 |
| 52-week low | $1.00 | $7.54 |
| Distance from 52-week high | -52.99% | -54.26% |
| Analyst consensus | none | none |
| Avg. price target upside | +166.27% | +225.95% |
| Average volume | 251.53K | 259.72K |
| Shares outstanding | 37.74M | 17.11M |
| Employees | 21 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
ANTX vs RNA FAQ
Which is bigger, AN2 Therapeutics or Atrium Therapeutics?
Atrium Therapeutics (RNA) is larger, with a market capitalization of $131.20M compared with $127.55M for AN2 Therapeutics (ANTX).
Are AN2 Therapeutics and Atrium Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.